Details for New Drug Application (NDA): 205410
✉ Email this page to a colleague
The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.
Summary for 205410
Tradename: | HEMANGEOL |
Applicant: | Pierre Fabre |
Ingredient: | propranolol hydrochloride |
Patents: | 2 |
Pharmacology for NDA: 205410
Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for 205410
Suppliers and Packaging for NDA: 205410
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
HEMANGEOL | propranolol hydrochloride | SOLUTION;ORAL | 205410 | NDA | Pierre Fabre Pharmaceuticals, Inc. | 64370-375 | 64370-375-01 | 1 BOTTLE, GLASS in 1 CARTON (64370-375-01) / 120 mL in 1 BOTTLE, GLASS |
HEMANGEOL | propranolol hydrochloride | SOLUTION;ORAL | 205410 | NDA | Pierre Fabre Pharmaceuticals, Inc. | 64370-375 | 64370-375-50 | 1 BOTTLE, GLASS in 1 CARTON (64370-375-50) / 50 mL in 1 BOTTLE, GLASS |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 4.28MG/ML | ||||
Approval Date: | Mar 14, 2014 | TE: | RLD: | Yes | |||||
Patent: | 8,338,489 | Patent Expiration: | Oct 16, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD TO TREAT HEMANGIOMA. | ||||||||
Patent: | 8,987,262 | Patent Expiration: | Oct 16, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD TO TREAT INFANTILE HEMANGIOMA |
Complete Access Available with Subscription